Prostate Cancer Research has announced that former UK prime minister Rishi Sunak has joined the charity as an ambassador.

communique.awardsplatform.com

The University of Manchester, UK, has announced the launch of its British Heart Foundation (BHF) Manchester Centre of Research Excellence following a £4m backing from the heart and circulatory research charity.

PharmaRole.com

The curated BIO-Europe Spring programme brings together a powerhouse of thought leaders and features the innovative spirit of the life sciences community. Here is a sneak peek at what to expect.

Welcome to the March issue of Pharmafocus! As the country enjoys warmer temperatures and sunnier skies at the beginning of spring, this time of year is always a time of growth and renewal and the pharma industry is no different.

EDX Medical – a clinical diagnostics company founded by Sir Christopher Evans, OBE – has announced the development of a new ‘super test’ for prostate cancer.

Global pharma company Thermo Fisher Scientific has announced the launch of CorEvitas Adolescent Alopecia Registry, which aims to address an unmet need in the research for adolescent alopecia.

To mark last month’s World Cancer Day, a new plan was unveiled by the UK Government to help tackle the impact of cancer across England.

flypharmaeurope.com

Recce Pharmaceuticals has announced positive patient data from its phase 2 clinical trial into RECCE 327 (R327), for the treatment of acute bacterial skin and skin structure infections (ABSSSIs), including diabetic foot infections (DFI).

Ophthalmology biotech PulseSight Therapeutics has confirmed the closure of its Series A funding round, the proceeds of which will be used to fund a phase 1 study into its dry age-related macular degeneration (AMD) therapy, PST-611. The funding round was supported by existing investor Pureos BioVentures.

Paragon Bioscience’s clinical biopharma spin-out, Emalex Bioscience, has announced that its lead candidate for the treatment of Tourette syndrome has met its primary and secondary endpoints in a recent phase 3 study.

Real-world data into a mandatory non-medical switching policy for patients with inflammatory bowel disease (IBD) has shown long-term safety and efficacy. The patients transitioned from using adalimumab (Humira) to a biosimilar due to the enaction of the policy in British Columbia, Canada – the first Canadian province to do so.

UCB’s Fintepla (fenfluramine) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged two years and older.

The European Commission (EC) has approved acoramidis to treat wild-type or variant transthyretin amyloidosis in adults with cardiomyopathy (ATTR-CM), according to an announcement from the drug’s developer BridgeBio Pharma.

The US Food and Drug Administration (FDA) has approved Samsung Bioepis’ biosimilars referencing Amgen’s bone disease therapy denosumab.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Telix Pharmaceuticals’ imaging agent Illuccix (gozetotide) for use in adult prostate cancer patients who are undergoing a position emission tomography (PET) scan.

Korean company Rznomics has announced that its gene therapy-based cancer drug candidate has been granted Fast Track designation (FTD) by the US Food and Drug Administration (FDA). It is indicated for use in hepatocellular carcinoma (HCC).

Sanofi has announced that the US Food and Drug Administration (FDA) has accepted its supplemental biologics licence application (sBLA) for priority review for the treatment of bullous pemphigoid (BP). The sBLA is for Dupixent (dupilumab), which has already received regulatory approvals in more than 60 countries for certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic oesophagitis, prurigo nodularis, chronic spontaneous urtica

Leading provider of digital identification and traceability software solutions, Systech, has announced the launch of UniSecure artAI.

Biotechnology company Eikon Therapeutics has announced the initial closing of its Series D funding round, securing $350.7m to support its current therapeutic pipeline and contribute to its goal of integrating advanced engineering with molecular and cell biology.

Northern Irish biostatistics and data science company, Exploristics, has announced that it has been acquired by MMS.

Business and technology consultancy HERAX Life Science has been acquired by ProductLife Group (PLG).

3M spin-off Solventum has announced that global supplier of analytical instruments Thermo Fisher Scientific has agreed to purchase its purification and filtration businesses unit for $4.1bn.

www.samedanltd.com

Eleva, a clinical-stage biopharmaceutical company, has announced the appointment of Martin Bauer as its new chief medical officer.

ViCentra, a company focused on its automated insulin delivery system, has announced the appointment of Tom Arnold as chief executive officer.

Novo Nordisk has announced the appointment of Sebnem Avsar Tuna as general manager for its UK affiliate.

Glox Therapeutics, a precision medicine company spun out from the Universities of Oxford and Glasgow, has announced the appointments of Michael Murray (pictured) as chair of the board and Nel Moore as scientific advisory board member.

Nuclera has announced the appointment of Seth Benson as its new chief financial officer, following the strengthening of its leadership team with three key appointments at the end of last year.

Sapio Sciences, a provider of lab informatics solutions, has announced the appointment of Mike Hampton as chief commercial officer and unveiled its new scientific office.

The curated BIO-Europe Spring programme brings together a powerhouse of thought leaders and features the innovative spirit of the life sciences community. Here is a sneak peek at what to expect

Too often in discussions about the COVID-19 pandemic it is treated like a finished and finalised event. Anu Osinusi at Gilead Sciences explores how its impacts are still being felt by patients and healthcare organisations around the globe

Julie Missaggia at CMI Media Group, a WPP Company, and Compas, explores how workplaces engage with the symptoms of menopause, and why this needs to be improved

In Pharmafocus’ inaugural Leader in Focus, Şeyda Atadan Memiş at Takeda UK and Ireland reflects on her career and explains the importance of providing more support to get women into STEM

With a region as large and diverse as Europe, Mike Ryan and Paolo Correale at EVERSANA explain how pharma companies can best engage with the myriad of expectations and regulations associated with launching in the EU

This edition's Five Facts are about Women's Heath!

Follow us on X to keep up to date with breaking news and join in with our pharma polls! @Pharmafocus

www.terrapinn.com/WVCDC

www.aaps.org/aaps